drugset / Trial / NCT00732888

Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy Volunteers

NCT00732888

Phase 1 Completed 14 enrolled Jan Beumer Novartis Pharmaceuticals · collab
RandomizedCrossoverOpen-label

Summary

This research study is being conducted through the University of Pittsburgh Cancer Institute (UPCI). It will evaluate the concentrations of Tasigna®, an oral drug used to treat some types of cancer, in the blood of healthy volunteers when taken with and without Tums Ultra®, a calcium product often used in the treatment of upset stomach and as a calcium supplement.

Timeline

Start
2008-11
Primary completion
2011-08
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Nilotinib Small molecule 400 mg Oral

Indications

No indication recorded.